We are a drug discovery company selectively targeting protein myristoylation for the treatment of cancer and viral diseases
Location: United Kingdom, England, Stevenage
Employees: 1-10
Total raised: $5.95M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 17.11.2020 | Sofinnova ... | sofinnovap... |
| - | Brandon Ca... | brandoncap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.11.2020 | Seed | $5.95M | - |
Mentions in press and media 4
| Date | Title | Description |
| 28.09.2022 | Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics | Melbourne, Australia and London UK, 28 September 2022 –Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that ha... |
| 16.11.2020 | Myricx Pharma : Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer | Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, today unveiled an initial £4.5 million in seed financing from expe... |
| 16.11.2020 | Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer | Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, today unveiled an initial £4.5 million (AU$8.2 million) in seed fi... |
| 16.11.2020 | Myricx Pharma Raises £4.5M in Seed Financing | Myricx Pharma, a Stevenage, United Kingdom-based drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, raised £4.5m in seed financing. Backers inclu... |